Procter & Gamble Health Ltd. (IN:PGHL)
:PGHL
Want to see IN:PGHL full AI Analyst Report?
PGHL Stock Chart & Stats
₹5751.70
-₹54.70(-1.07%)
At close: 4:00 PM EST
₹5751.70
-₹54.70(-1.07%)
Day’s Range― - ―
52-Week Range₹4,699.70 - ₹6,701.40
Previous CloseN/A
Volume2.65K
Average Volume (3M)310.00
Market Cap
₹102.71B
Enterprise Value₹98.77B
Total Cash (Recent Filing)₹2.86B
Total Debt (Recent Filing)₹95.50M
Price to Earnings (P/E)31.9
Beta0.49
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.28%
Share Statistics
EPS (TTM)184.83
Shares Outstanding16,599,382
10 Day Avg. Volume340
30 Day Avg. Volume310
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)15.22
Price to Sales (P/S)5.67
P/FCF Ratio24.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)215.9
Revenue Forecast (FY)₹15.00B
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsConsistently high gross and net margins indicate durable pricing power and brand strength in OTC healthcare. This margin profile supports sustained cash generation and reinvestment capacity, enabling marketing and distribution investments that preserve competitive position over months.
Conservative Balance Sheet, Low LeverageVery low leverage and a conservative capital structure reduce refinancing and solvency risk, giving management flexibility to fund growth or shareholder returns. The strong balance sheet is a durable buffer against industry cycles and supports strategic optionality over the medium term.
Rebounding Free Cash FlowA marked YoY rebound in free cash flow strengthens the company's ability to self-fund marketing, capex and distribution expansion. Improving cash conversion enhances financial resilience and supports sustained investment in brand and supply chain over the coming quarters.
Bears Say
Prior Revenue Dip In 2024A documented revenue decline in 2024 highlights demand or execution vulnerabilities in the core OTC business. Such interruptions can signal competitive pressure or channel disruption, making near-term topline recovery and predictable growth over the next several quarters less certain.
Volatile Cash Conversion HistoricallyHistorical swings in operating cash conversion and intermittent FCF declines complicate forecasting and capital allocation. Persistent volatility could constrain sustained marketing spend or capex and increase reliance on tight working capital management during weaker periods.
Concentration In Indian OTC MarketHeavy reliance on the India OTC channel concentrates revenue risk to one geography and distribution ecosystem. Regulatory changes, channel margin shifts, or local competitive moves could materially affect sales and margin stability across the medium term.
Procter & Gamble Health Ltd. News
PGHL FAQ
What was Procter & Gamble Health Ltd.’s price range in the past 12 months?
Procter & Gamble Health Ltd. lowest stock price was ₹4699.70 and its highest was ₹6701.40 in the past 12 months.
What is Procter & Gamble Health Ltd.’s market cap?
Procter & Gamble Health Ltd.’s market cap is ₹102.71B.
When is Procter & Gamble Health Ltd.’s upcoming earnings report date?
Procter & Gamble Health Ltd.’s upcoming earnings report date is Nov 11, 2026 which is in 150 days.
How were Procter & Gamble Health Ltd.’s earnings last quarter?
Procter & Gamble Health Ltd. released its earnings results on May 26, 2026. The company reported ₹56.99 earnings per share for the quarter, beating the consensus estimate of N/A by ₹56.99.
Is Procter & Gamble Health Ltd. overvalued?
According to Wall Street analysts Procter & Gamble Health Ltd.’s price is currently Overvalued.
Does Procter & Gamble Health Ltd. pay dividends?
Procter & Gamble Health Ltd. pays a Semiannually dividend of ₹160 which represents an annual dividend yield of 3.28%. See more information on Procter & Gamble Health Ltd. dividends here
What is Procter & Gamble Health Ltd.’s EPS estimate?
Procter & Gamble Health Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Procter & Gamble Health Ltd. have?
Procter & Gamble Health Ltd. has 16,599,382 shares outstanding.
What happened to Procter & Gamble Health Ltd.’s price movement after its last earnings report?
Procter & Gamble Health Ltd. reported an EPS of ₹56.99 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.219%.
Which hedge fund is a major shareholder of Procter & Gamble Health Ltd.?
Currently, no hedge funds are holding shares in IN:PGHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Procter & Gamble Health Ltd.
Procter & Gamble Health Limited is an Indian entity focused on the production and distribution of pharmaceutical products and chemicals. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, as well as vitamins, minerals, and dietary supplements. The company's offerings are available under recognized brand names such as Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas. In addition to its domestic operations, Procter & Gamble Health Limited also exports its pharmaceutical goods to several international markets, including Sri Lanka, Nepal, Myanmar, and Maldives. Established in 1967, the company originally operated as Merck Limited, rebranding to Procter & Gamble Health Limited in May 2019. It is headquartered in Mumbai, India, and functions as a subsidiary of Procter & Gamble Overseas India B.V.
Technical Analysis
Amrutanjan Health Care Limited
―
Aurobindo Pharma Ltd
―
Glenmark Pharmaceuticals Limited
―
Mankind Pharma Ltd.
―
Zydus Lifesciences Limited
―